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A B S T R A C T
Aims: Determine the inﬂuence of metabolic syndrome and its different components in the outcomes of
colorectal cancer surgery at 30 days.
Materials and methods: Prospective study that included all patients submitted to elective colorectal
cancer surgery between August 2015 and August 2016 at Hospital de Braga. Clinical and laboratory
parameters evaluated pre-operatively were: central obesity, blood pressure, fasting glucose, triglycerides
levels and HDL cholesterol levels. Any complications during the ﬁrst 30-days after surgery were recorded
(readmission, reintervention, anastomotic dehiscence, morbimortality).
Results: One hundred and thirty-four patients were included. Metabolic syndrome was diagnostic in
40.7% of patients with the ATPIII deﬁnition, 67.5% with the AHA deﬁnition and 67.0% with the IDF
deﬁnition. At 30 days after colorectal cancer surgery, 73.1% patients don’t have any complication, 15.7%
have minor complications (grade I/II of Clavien-Dindo classiﬁcation), 11.1% have major complications
(grade III/IV/V of Clavien-Dindo classiﬁcation) and 1.5% have died from surgical complications (grade V of
Clavien-Dindo classiﬁcation). The statistic analysis didn’t reveal any association between MS, or it’s
different components, and surgical outcomes.
Conclusion: This study seems to indicate that metabolic syndrome don’t have any inﬂuence in surgical
outcomes of colorectal cancer surgery.
© 2017 Diabetes India. Published by Elsevier Ltd. All rights reserved.
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The terms “metabolic syndrome” (MS) stand for a cluster of
interrelated risk factors of metabolic origin that have been proved
to predict a higher risk of atherosclerotic cardiovascular disease as
well as type 2 diabetes mellitus expressing, this way, its clinical
importance. With a prevalence of approximately 24,6–30.9% in
Europe [1] the development of this syndrome appears to be
directly related to abdominal obesity and insulin resistance [2].
Since its initial description (approximately 80 years ago) [1]
many different deﬁnitions have been proposed by several
institutions, but they all agree on the same basic components,
namely hypertension, dyslipidemia, insulin resistance and central
obesity.* Corresponding author at: General Surgery, Hospital of Braga, 4701-965 Braga,
Portugal.
E-mail address: andre.b.goulart@gmail.com (A. Goulart).
http://dx.doi.org/10.1016/j.dsx.2017.07.007
1871-4021/© 2017 Diabetes India. Published by Elsevier Ltd. All rights reserved.The most popular deﬁnitions are those from National Choles-
terol Education Program  Third Adult Treatment Panel (NCEP-
ATPIII), or just ATPIII, from 2001 [3], the International Diabetes
Federation (IDF), from 2005 [4], and, ﬁnally, the American Heart
Association/National Heart Lung and Blood Institute (AHA/NHLBI),
from also 2005 [2].
Besides the cardiovascular consequences of the metabolic
syndrome, in several cohort studies and meta-analyses, this entity
has been proven to increase cancer risk in general [5,6] with major
effects on the gastrointestinal tract, namely increasing the risk of
non-neoplastic gastrointestinal disorders, precursor lesions and
CRC itself [7]. This relationship between metabolic syndrome and
the risk of colorectal cancer is at the moment supported by a large
number of studies [1,8,9], and this linkage is mainly explained by
abdominal obesity and insulin resistance with a multifactorial
mechanism of carcinogenesis involving the action of adipokines,
inﬂammatory cytokines, adiponectin, leptin, IGF-1 and others [1].
Colorectal cancer represents an important health issue, as being
the third most common cancer in men and the second in women
worldwide (10.0% and 9.2% of the total, respectively) [10]. These
Table 1
Sample characterization; ND = No data.
Statistics
Age M (SD) 67.91 (12.94)
Gender n (%)
M 82 (61.2%)
F 52 (38.8%)
MS n (%)
ATPIII Deﬁnition n = 113
No 67 (59.3%)
Yes 46 (40.7%)
ND 21
AHA Deﬁnition n = 117
No 38 (32.5%)
Yes 79 (67.5%)
ND 17
IDF Deﬁnition n = 106
No 35 (33.0%)
Yes 71 (67.0%)
ND 28
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urbanization, aging, diet changes and lifestyle [11].
At least one study of our knowledge has already proved the
deleterious inﬂuence of MS on CRC prognosis, with signiﬁcantly
shorter survival and higher recurrence and liver metastasizing
rates, implying that MS is an important prognostic factor for CRC
[12]. Moreover, this deleterious inﬂuence was also proved for the
outcomes of CRC surgery at 30 days, showing a higher rate of
postoperative complications and a longer hospital stay in patients
classiﬁed with the AHA/NHLBI deﬁnition of MS. Also in this study
from 2009, high blood pressure and high triglyceride levels were as
well considered important risk factors for severe complications
after CRC surgery, but only the presence of the cluster of metabolic
abnormalities that constitute MS was proven to be an independent
variable in the multivariate analysis, and not each individual
component [13].
Concerning the inﬂuence of obesity in surgery outcomes, WC
proved to be an independent risk factor for the development of
parastomal hernia after permanent colostomy [14]. Another study
published in 2013 proved that waist-hip-ration (as a measure of
central obesity) had a signiﬁcant inﬂuence in negative outcomes
after CRC surgery, namely reoperation, medical complications,
intraoperative complications and conversion to open approach,
being this prediction effect superior to the one veriﬁed when
measuring BMI and or WC [15]. Obesity was also associated with an
increase in anastomotic leakage after rectal cancer resection [16].
Furthermore, a study concerning the ﬁnancial implications of
CRC surgery in obese patients has detected a signiﬁcant increase in
hospital expenses due to a higher rate of severe complications. The
major contributors for these costs were wards stay, operations, and
intensive care units [17].
The aim of this study is to determine the inﬂuence of MS and
different components of MS (high fasting glucose, central obesity,
high blood pressure, high triglycerides levels and low HDL
cholesterol levels) in the outcomes of CRC surgery at 30 days
(reintervention, readmission, dehiscence and morbimortality).
2. Methods
2.1. Study oversight and patients inclusion
This study included all the patients with a conﬁrmed diagnosis
of colorectal adenocarcinoma who underwent elective surgery at
Hospital de Braga during August 2015 till August 2016. Patients
who presented evidence of metastasis before or at surgery,
necessity of removal of other organs due to tumor invasion,
synchronous tumors or history of other malignant tumors within 5
years, history of familial adenomatous polyposis and hereditary
non-polyposis colorectal carcinoma were excluded.
2.2. Data collection
At the ﬁrst moment of evaluation, during pre-operative
consultation, data were collected concerning patient’s age, gender,
history of arterial hypertension, diabetes mellitus, dyslipidemia,
prior neoplasms, usual medication (with special concern for
hypertension, diabetes, high triglycerides and low HDL cholesterol
speciﬁc treatments) and family history of neoplasms. On the day
prior to their admission to the hospital for surgery, the patients
were requested to present themselves at Clinical Academic Center
at Hospital de Braga for an anthropometric evaluation, carried out,
all times, by the same nurse, which included height, weight and
waist circumference measurement, as well as collection of blood
samples for evaluation of fasting glucose, HDL cholesterol and
triglycerides levels. During a period of 30 days following surgery,
data about complications were collected and registered, namelymorbimortality, readmission, reintervention and anastomotic
dehiscence. Morbimortality was posteriorly classiﬁed according
to Clavien-Dindo’s classiﬁcation [18].
2.3. Statistical analysis
Statistical analysis was performed using SPSS – Statistical
Package for the Social Science Program, version 23.
Descriptive statistics are presented as absolute frequencies (n)
and relative (%) for categorical variables, and mean (M) and
standard deviation (SD), or median (Mdn) and interquartile ranges,
for quantitative variables, depending on whether or not symmetry
of the distributions was ensured. The chi-square test was used to
identify associations between dichotomous outcomes (morbimor-
tality, dehiscence, reintervention and readmission) and the
independent variables. When the maximum assumed 20% of cells
with the expected frequency of less than 5 was exceeded, Fisher's
test (2  2 tables) was used. The Mann-Whitney test was used to
compare the outcome measured on an ordinal scale (Morbimor-
tality according to Clavien-Dindo classiﬁcation) with the indepen-
dent variables. Finally, logistic regressions were used to measure
the risk of the independent variables on the dichotomous
outcomes. The signiﬁcance level for rejection of H0 was 5%
(p < 0.05).
2.4. Ethical issues
The present study was approved by the Ethic Committee of
Hospital de Braga. The investigators made sure to safeguard the
anonymity and conﬁdentiality of all the participants. A written
informed consent was obtained from each patient.
3. Results
The present study included a sample of 134 patients with CRC
diagnoses, with a mean age of 67.91 years old, 82 males and 52
females. 46 (40.7% in 113) of these patients were diagnoses with
MS according to the ATPIII deﬁnition, 79 (67.5% in 117) according to
the AHA deﬁnition and 71 (67.0% in 106) according to the IDF
deﬁnition. These data are shown in Table 1. We were not able to
collect the necessary information for these diagnoses in some of
the patients (ND in the table), most often by absence of the patient
from the appointments with the nurse for measurement of
anthropometric parameters and blood samples collection.
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from any complication.11 patients were readmitted to the hospital,
10 patients suffered anastomotic dehiscence and 10 patients were
again submitted to surgery. With a total morbimortality percent-
age of 26.9%, only 2 deaths were registered during this period.
Complications distribution according to Clavien-Dindo Classiﬁca-
tion and the previous data about 30 days after surgery outcomes
are shown in Table 2.Table 2
Sample surgical outcomes.
n (%)
Readmission 11 (8.3%)
Dehiscence 10 (7.5%)
Reintervention 10 (7.5%)
Morbimortality 36 (26.9%)
Clavien-Dindo Classif.
No complications 98 (73.1%)
Grade I 8 (6.0%)
Grade II 13 (9.7%)
Grade IIIa 3 (2.2%)
Grade IIIb 6 (4.5%)
Grade IVa 1 (0.7%)
Grade IVb 3 (2.2%)
Grade V 2 (1.5%)
Length of Hospital Stay Mdn (IQR) 5.00 (3.00)
Table 3
Chi square tests results. relation between dichotomous outcomes and independent var
Readmission Reinterven
No Yes p
value
No 
MS ATPIII Deﬁnition 43 (93.5%) 3 (6.5%) 0.456 42 (91.3%) 
Central Obesity (ATPIII Deﬁnition) 44 (91.7%) 4 (8.3%) 0.787 45 (93.8%) 
High Triglycerides level (ATPIII Deﬁnition) 42 (91.3) 4 (8.7%) 0.870 45 (97.8%) 
Low HDL Cholesterol level (ATPIII
Deﬁnition)
53 (89.8%) 6
(10.2%)
0.797 54 (90.0%) 
High Blood Pressure (ATPIII Deﬁnition) 82 (91.1%) 8 (8.9%) 0.463 82 (91.1%) 
High Fasting Glucose (ATPIII Deﬁnition) 44 (91.7%) 4 (8.3%) 0.787 45 (93.8%) 
MS AHA Deﬁnition 73 (92.4%) 6 (7.6%) 0.595 75 (94.9%) 
Central Obesity (AHA Deﬁnition) 44 (91.7%) 4 (8.3%) 0.787 45 (93.8%) 
High Triglycerides level (AHA Deﬁnition) 42 (91.3%) 4 (8.7%) 0.870 45 (97.8%) 
Low HDL Cholesterol level (AHA
Deﬁnition)
85 (90.4%) 9 (9.6%) 0.595 87 (91.6%) 
High Blood Pressure (AHA Deﬁnition) 105
(92.1%)
9 (7.9%) 0.771 106
(92.2%)
High Fasting Glucose (AHA Deﬁnition) 52 (89.7%) 6
(10.3%)
0.686 54 (93.1%) 
MS IDF Deﬁnition 64 (90.1%) 7 (9.9%) 0.831 66 (93.0%) 
Central Obesity (IDF Deﬁnition) 75 (90.4%) 8 (9.6%) 0.764 78 (94.0%) 
High Triglycerides level (IDF Deﬁnition) 42 (91.3%) 4 (8.7%) 0.870 45 (97.8%) 
HDL Cholesterol level (IDF Deﬁnition) 85 (90.4%) 9 (9.6%) 0.595 87 (91.6%) 
High Blood Pressure (IDF Deﬁnition) 105
(92.1%)
9 (7.9%) 0.771 106
(92.2%)
High Fasting Glucose (IDF Deﬁnition) 52 (89.7%) 6
(10.3%)
0.686 54 (93.1%) After applying chi-square tests, the results suggest no evidence
of association between any of the MS deﬁnition diagnosis (or their
different components) and the surgical outcomes studied, except
for low HDL cholesterol levels by ATPIII deﬁnition (HDL –
c < 40 mg/dL in men or <50 mg/dL in women) as a predictor of
morbimortality at 30 days, (p = 0.037) (Table 3).
Logistic regression was computed in order to calculate Odds
ratio (OR) for the risk of having morbimortality having low HDL
cholesterol (by ATPIII deﬁnition) as a predictor.
The risk of morbimortality for patients with low HDL
cholesterol is 2.42 times increased when compared with patients
with high HDL cholesterol (95% CI = [1.04, 5.62]). This result was
statistically signiﬁcant for p = 0.039 (Table 4).
As preforming Mann-Whitney Test for ordinal outcomes
(Morbimortality according to Clavien-Dindo Classiﬁcation) we
were able to also stablish a statistically signiﬁcant result, which
states that patients with low HDL-cholesterol (by ATPIII deﬁnition)iables.
tion Dehiscence Morbimortality
Yes p
value
No Yes p
value
No Yes p value
4 (8.7%) 0.361 40
(93.0%)
3 (7%) 0.854 34
(73.9%)
12
(26.1%)
0.790
3 (6.3%) 0.462 44
(93.6%)
3 (6.4%) 0.861 40
(83.3%)
8 (16.7%) 0.056
1 (2.2%) 0.120 41
(97.6%)
1 (2.4%) 0.088 33
(71.7%)
13
(28.3%)
0.883
6
(10.0%)
0.164 49
(89.1%)
6
(10.9%)
0.297 38
(63.3%)
22
(36.7%)
.037
8 (8.9%) 0.185 77
(90.6%)
8 (9.4%) 0.204 62
(68.9%)
28
(31.1%)
0.106
3 (6.3%) 0.462 44
(93.6%)
3 (6.4%) 0.861 40
(83.3%)
8 (16.7%) 0.056
4 (5.1%) 0.963 70
(94.6%)
4 (5.4%) 0.529 63
(79.7%)
16
(20.3%)
0.054
3 (6.3%) 0.462 44
(93.6%)
3 (6.4%) 0.861 40
(83.3%)
8 (16.7%) 0.056
1 (2.2%) 0.120 41
(97.6%)
1 (2.4%) 0.088 33
(71.7%)
13
(28.3%)
0.883
8 (8.4%) 0.095 80
(90.9%)
8 (9.1%) 0.095 68
(71.6%)
27
(28.4%)
0.319
9 (7.8%) 0.232 99
(91.7%)
9 (8.3%) 0.246 86
(74.8%)
29
(25.2%)
0.380
4 (6.9%) 0.922 50
(94.3%)
3 (5.7%) 0.381 44
(75.9%)
14
(24.1%)
0.425
5 (7.0%) 0.108 60
(92.3%)
5(7.7%) 0.363 54
(76.1%)
17
(26.9%)
0.411
5 (6.0%) 0.200 71
(92.2%)
6 (7.8%) 0.159 65
(78.3%)
18
(21.7%)
0.088
1 (2.2%) 0.120 41
(97.6%)
1 (2.4%) 0.088 33
(71.7%)
13
(28.3%)
0.883
8 (8.4%) 0.095 80
(90.9%)
8 (9.1%) 0.323 68
(71.6%)
27
(28.4%)
0.319
9 (7.8%) 0.232 99
(91.7%)
9 (8.3%) 0.246 86
(74.8%)
29
(25.2%)
0.380
4 (6.9%) 0.922 50
(94.3%)
3 (5.7%) 0.381 44
(75.9%)
14
(24.1%)
0.425
Table 4
Logistic Model; In this case: Yes = HDL – C < 40 mg/dL in men or <50 mg/dL in
women and No = HDL – C  40 mg/dL in men or 50 mg/dL in women.
OR 95% CI p-value
Low HDL cholesterol
No 1 1 1
Yes 2.42 (1.04–5.62) p = 0.039
Table 5
Mann-Whitney Test Results. Relation between ordinal outcome (Morbimortality according to Clavien-Dindo classiﬁcation) and Independent Variables.
Man- Whitney Test
Morbimortality According to Clavien-dindo Classiﬁcation
Mdn (IQR)
No Yes p value U Z
MS ATPIII Deﬁnition 0 (1) 0 (1) 0.777 1503.00 0.283
Central Obesity (ATPIII Deﬁnition) 0 (2) 0 (0) 0.091 1251.50 1.691
High Triglycerides level (ATPIII Deﬁnition) 0 (1) 0 (1) 0.880 1680.00 0.151
Low HDL Cholesterol level (ATPIII Deﬁnition) 0 (0) 0 (2) .033 1400.50 2.129
High Blood Pressure (ATPIII Deﬁnition) 0 (0) 0 (1) 0.133 15670.50 1.504
High Fasting Glucose (ATPIII Deﬁnition) 0 (2) 0 (0) 0.091 1251.50 1.691
MS AHA Deﬁnition 0 (2) 0 (0) 0.067 1260.00 1.830
Central Obesity (AHA Deﬁnition) 0 (2) 0 (0) 0.091 1251.50 1.691
High Triglycerides level (AHA Deﬁnition) 0 (1) 0 (1) 0.880 1680.00 0.151
Low HDL Cholesterol level (AHA Deﬁnition) 0 (0) 0 (2) 0.239 1312.00 0.239
High Blood Pressure (AHA Deﬁnition) 0 (2) 0 (1) 0.398 881.00 0.845
High Fasting Glucose (AHA Deﬁnition) 0 (1) 0 (1) 0.452 1685.50 0.752
MS IDF Deﬁnition 0 (1) 0 (1) 0.538 1171.50 0.616
Central Obesity (IDF Deﬁnition) 0 (2) 0 (0) 0.137 918.50 1.488
High Triglycerides level (IDF Deﬁnition) 0 (1) 0 (1) 0.880 1680.00 0.151
HDL Cholesterol level (IDF Deﬁnition) 0 (0) 0 (2) 0.239 1312.00 1.177
High Blood Pressure (IDF Deﬁnition) 0 (2) 0 (1) 0.398 881.00 0.845
High Fasting Glucose (IDF Deﬁnition) 0 (1) 0 (1) 0.452 1685.50 0.752
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classiﬁcation (Mdn = 0; IQR = 2; p = 0.033), (Table 5).
4. Discussion
It is well known nowadays that MS is a risk factor for the
development of CRC, as proven, between many others, by a large
cohort study from 2006 [9] or by a recent meta-analysis (reporting
17 studies) from 2013 [8] being the pathophysiological mechanism
pointed has responsible mostly related to insulin resistance and
abdominal obesity [1]. This fact may perhaps explain the high
incidence of MS (in all its deﬁnitions) in our sample (constituted
only by CRC diagnosed patients) in comparison, for example, with a
report that included 1433 inhabitants of Porto city (Portugal). In
this study, the investigators obtained an estimated prevalence of
MS of 24.0% with the ATPIII criteria, 37.2% with the AHA criteria
and, 41.9% with the IDF criteria [19], in contrast with our results of
40.7%, 67.5% and 67.0%, respectively.
On the other hand, the relationship between MS and CRC
surgical outcomes, recurrence and survival has been a source of
disagreement with discording studies being published over the
time.
For instance, a study from 2010 showed that the presence of
metabolic syndrome was associated with a signiﬁcant increase of
hepatic metastasis and tumor recurrence [12]. In the same year
another prospective study from Thailand peremptorily concluded
that MS was an independent rick factor for postoperative
complications and longer hospital stay in CRC patients submitted
to surgery, with a 30 days follow-up [13]. On the other hand, in
2013, a retrospective cohort investigation concluded that MS had
no inﬂuence on recurrence and overall survival of CRC patients,
perhaps explained by the combined effects of elevated blood
glucose and hypertension and the protective effect of dyslipidemia,
has proven in the same study [20]. Moreover, two survival analysis
from 2016 were able to, again, prove a deleterious effect of MS. On
one of them, a prospective study involving 1318 CRC patients, it
was proved that MS, specially hyperglycemia, were robust
predictors of CRC mortality [21]. On the other one, from October
2016, patients were divided into 4 categories (deﬁned by the
presence of MS and/or obesity) and, as a result, the group with MSand obesity combined obtained a worse survival, overall and CRC
related [22].
The pointed mechanism for this interaction might be explain by
several theories: ﬁrst, the insulin-resistant state present in MS
inﬂuences an abnormal metabolism in adipocytes (especially
visceral fat adipocytes) with subsequent increase in levels of
Interleukin-6 and tumor necrosis factor-a (both pro-inﬂammato-
ry) and low levels of adiponectin (protective adipokine) leading to
an excessive systemic inﬂammatory response. Secondly, MS has
been correlated with a situation of impaired microvascular
circulation, which may cause diminished perfusion and poor
tissue healing. And ﬁnally, alterations in polymorphonuclear cells
has been noticed in patients with MS, which might be caused by
the low levels of Leukotriene B4, essential in these cells function,
leading this way to alterations in innate immune defense [13].
In our study there was no statistically signiﬁcant inﬂuence of
any of the MS deﬁnitions or it’s components on the studied
outcomes (no p value < 0.05), and the only ﬁnding that proves
inﬂuence of HDL-cholesterol (by ATPIII deﬁnition) with 30 days
morbimortality and with Clavien-Dindo Classiﬁcation Grade
appears to us a statistical ﬁnding instead of a valuable ﬁnding
concerning the context.
5. Conclusion
This study seems to indicate that there is no apparent
association between MS, in its different deﬁnitions and compo-
nents, and CRC surgical outcomes (reintervention, readmission,
dehiscence and morbimortality) at 30 days.
While a deeper understanding of this relationship could lead to
a better clinical management, data remains inconclusive. The
question of whether or not a better control of metabolic status
could improve CRC patients’ prognosis waits for further studies
with larger sample sizes and longer follow-up timings.
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